Explore more about: Point of Care Technologies - Diagnostics

Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM).

The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.

ANP Technologies announced on Monday that its SARS-CoV-2 rapid antigen test has received Emergency Use Authorization from the US Food and Drug Administration.

With the Covid-19 pandemic causing ventilator shortages around the globe, three biomedical engineering graduates from the University of South Florida are receiving national recognition for their efforts to mitigate the scarcity of these lifesaving machines.

Placenta accreta spectrum (PAS) disorder is a life-threatening condition that occurs when the placenta remains attached to the uterus after childbirth. Now researchers have developed a blood test to identify this condition, enabling early intervention by high-risk pregnancy specialists.

In a study that compares rapid antigen and laboratory PCR approaches for COVID-19 serial screening, researchers affiliated with the NIH RADx initiative reported results from 43 people infected with the virus.

One-year into implementation of the NIH RADx initiative, the IEEE Open Journal of Engineering in Medicine and Biology has dedicated a specialissue to exploring the innovative structure and operation of the RADx Tech program.

An NIH-funded research team has launched a study to assess performance and usability of a smartphone app paired with the Quidel QuickVue At-Home COVID-19 Test, which received FDA emergency use authorization for use with a prescription.

The FDA granted emergency use authorization today for an innovative COVID-19 viral antigen test developed with support from the NIH RADx Initiative.

In a new study, a team of researchers outlines the technology for a CRISPR-based test for COVID-19 that uses a smartphone camera to provide accurate results in under 30 minutes.